Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
19
HLOSF Quote, Financials, Valuation and Earnings
Last price:
$1.93
Seasonality move
:
12.28%
Day range:
$1.93 - $1.93
52-week range:
$0.96 - $4.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
303.04x
P/B ratio:
11.21x
Volume:
--
Avg. volume:
32
1-year change:
42.96%
Market cap:
$222.8M
Revenue:
$3.7M
EPS (TTM):
-$0.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
AMGXF
AnGes, Inc.
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | 3.82% | -- | $17.93 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HLOSF
Healios KK
|
$1.93 | -- | $222.8M | -- | $0.00 | 0% | 303.04x |
|
AMGXF
AnGes, Inc.
|
$0.36 | -- | $139.1M | -- | $0.00 | 0% | 21.61x |
|
PPTDF
PeptiDream Inc.
|
$11.98 | -- | $1.5B | 13.79x | $0.00 | 0% | 12.90x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.08 | -- | $459.3M | -- | $0.00 | 0% | 2.37x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$15.58 | $17.93 | $49.2B | 197.72x | $0.32 | 4.24% | 1.68x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HLOSF
Healios KK
|
47.23% | -1.205 | 3.71% | 1.23x |
|
AMGXF
AnGes, Inc.
|
3.92% | 0.348 | 0.83% | 1.55x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.045 | 8.66% | 4.05x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.721 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.563 | 68.02% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
AMGXF
AnGes, Inc.
|
$669.9K | -$7.7M | -326.92% | -349.76% | -494.08% | -- |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
Healios KK vs. Competitors
-
Which has Higher Returns HLOSF or AMGXF?
AnGes, Inc. has a net margin of -9751.87% compared to Healios KK's net margin of -312.66%. Healios KK's return on equity of -194.37% beat AnGes, Inc.'s return on equity of -349.76%.
Company Gross Margin Earnings Per Share Invested Capital HLOSFHealios KK-494.88% $0.03 $37.8M AMGXFAnGes, Inc.42.74% -$0.01 $29.4M -
What do Analysts Say About HLOSF or AMGXF?
Healios KK has a consensus price target of --, signalling downside risk potential of --. On the other hand AnGes, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Healios KK has higher upside potential than AnGes, Inc., analysts believe Healios KK is more attractive than AnGes, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HLOSFHealios KK0 0 0 AMGXFAnGes, Inc.0 0 0 -
Is HLOSF or AMGXF More Risky?
Healios KK has a beta of 0.210, which suggesting that the stock is 78.954% less volatile than S&P 500. In comparison AnGes, Inc. has a beta of 0.060, suggesting its less volatile than the S&P 500 by 94.03%.
-
Which is a Better Dividend Stock HLOSF or AMGXF?
Healios KK has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AnGes, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Healios KK pays -- of its earnings as a dividend. AnGes, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HLOSF or AMGXF?
Healios KK quarterly revenues are $128.8K, which are smaller than AnGes, Inc. quarterly revenues of $1.6M. Healios KK's net income of $3.8M is higher than AnGes, Inc.'s net income of -$4.9M. Notably, Healios KK's price-to-earnings ratio is -- while AnGes, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Healios KK is 303.04x versus 21.61x for AnGes, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLOSFHealios KK303.04x -- $128.8K $3.8M AMGXFAnGes, Inc.21.61x -- $1.6M -$4.9M
-
Which has Higher Returns HLOSF or PPTDF?
PeptiDream Inc. has a net margin of -9751.87% compared to Healios KK's net margin of -25.38%. Healios KK's return on equity of -194.37% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital HLOSFHealios KK-494.88% $0.03 $37.8M PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About HLOSF or PPTDF?
Healios KK has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Healios KK has higher upside potential than PeptiDream Inc., analysts believe Healios KK is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings HLOSFHealios KK0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is HLOSF or PPTDF More Risky?
Healios KK has a beta of 0.210, which suggesting that the stock is 78.954% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.
-
Which is a Better Dividend Stock HLOSF or PPTDF?
Healios KK has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Healios KK pays -- of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HLOSF or PPTDF?
Healios KK quarterly revenues are $128.8K, which are smaller than PeptiDream Inc. quarterly revenues of $29.3M. Healios KK's net income of $3.8M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, Healios KK's price-to-earnings ratio is -- while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Healios KK is 303.04x versus 12.90x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLOSFHealios KK303.04x -- $128.8K $3.8M PPTDFPeptiDream Inc.12.90x 13.79x $29.3M -$7.4M
-
Which has Higher Returns HLOSF or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of -9751.87% compared to Healios KK's net margin of -24.76%. Healios KK's return on equity of -194.37% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital HLOSFHealios KK-494.88% $0.03 $37.8M SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About HLOSF or SOLTF?
Healios KK has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Healios KK has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Healios KK is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HLOSFHealios KK0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is HLOSF or SOLTF More Risky?
Healios KK has a beta of 0.210, which suggesting that the stock is 78.954% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.
-
Which is a Better Dividend Stock HLOSF or SOLTF?
Healios KK has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Healios KK pays -- of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HLOSF or SOLTF?
Healios KK quarterly revenues are $128.8K, which are smaller than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. Healios KK's net income of $3.8M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, Healios KK's price-to-earnings ratio is -- while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Healios KK is 303.04x versus 2.37x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLOSFHealios KK303.04x -- $128.8K $3.8M SOLTFNxera Pharma Co., Ltd.2.37x -- $45.8M -$11.3M
-
Which has Higher Returns HLOSF or STMM?
Stemcell Holdings, Inc. has a net margin of -9751.87% compared to Healios KK's net margin of --. Healios KK's return on equity of -194.37% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HLOSFHealios KK-494.88% $0.03 $37.8M STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About HLOSF or STMM?
Healios KK has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Healios KK has higher upside potential than Stemcell Holdings, Inc., analysts believe Healios KK is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HLOSFHealios KK0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is HLOSF or STMM More Risky?
Healios KK has a beta of 0.210, which suggesting that the stock is 78.954% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HLOSF or STMM?
Healios KK has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Healios KK pays -- of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HLOSF or STMM?
Healios KK quarterly revenues are $128.8K, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Healios KK's net income of $3.8M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Healios KK's price-to-earnings ratio is -- while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Healios KK is 303.04x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLOSFHealios KK303.04x -- $128.8K $3.8M STMMStemcell Holdings, Inc.0.17x -- -- --
-
Which has Higher Returns HLOSF or TAK?
Takeda Pharmaceutical Co., Ltd. has a net margin of -9751.87% compared to Healios KK's net margin of -1.05%. Healios KK's return on equity of -194.37% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.
Company Gross Margin Earnings Per Share Invested Capital HLOSFHealios KK-494.88% $0.03 $37.8M TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B -
What do Analysts Say About HLOSF or TAK?
Healios KK has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.93 which suggests that it could grow by 14.94%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Healios KK, analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings HLOSFHealios KK0 0 0 TAKTakeda Pharmaceutical Co., Ltd.3 0 0 -
Is HLOSF or TAK More Risky?
Healios KK has a beta of 0.210, which suggesting that the stock is 78.954% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, suggesting its less volatile than the S&P 500 by 96.811%.
-
Which is a Better Dividend Stock HLOSF or TAK?
Healios KK has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.24% to investors and pays a quarterly dividend of $0.32 per share. Healios KK pays -- of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend.
-
Which has Better Financial Ratios HLOSF or TAK?
Healios KK quarterly revenues are $128.8K, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. Healios KK's net income of $3.8M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, Healios KK's price-to-earnings ratio is -- while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 197.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Healios KK is 303.04x versus 1.68x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLOSFHealios KK303.04x -- $128.8K $3.8M TAKTakeda Pharmaceutical Co., Ltd.1.68x 197.72x $7.5B -$79.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
